Maria A.S. Broggi

Abstract 4340: AZD6750, a CD8α-guided IL-2 immunocytokine effectively combines with rilvegostomig, a PD-1/TIGIT bispecific antibody, to enhance endogenous immunity

Matthew J. Elder, Aidan Riley, Sin Lih Tan, Jérôme Mastio et autres

gb, jp, us (code pays fourni par la source)

An affinity-modulated T cell engager targeting Claudin 18.2 shows potent anti-tumor activity with limited cytokine release

Miguel B. Gaspar, Marina Natoli, Laure Castan, Sharif Rahmy et autres

gb, us, cn, kr, ch, es, br (code pays fourni par la source)

Ultrasensitive detection and tracking of circulating tumor DNA to predict relapse and survival in patients with locally advanced cervical cancer: phase III CALLA trial analyses

Jyoti Mayadev, Juan Carlos Vázquez Limón, Francisco Javier Ramírez Godinez, María Trinidad García Leiva et autres

us, mx, pe, vn, hu, nl, cl, cn, jp, il, br, in, fi, kr, gb (code pays fourni par la source)

Ultrasensitive detection and tracking of circulating tumor DNA (ctDNA) and association with relapse and survival in locally advanced cervical cancer (LACC): Phase 3 CALLA trial analyses.

Jyoti Mayadev, Juan Carlos Vázquez Limón, Francisco Javier Ramírez Godinez, Manuel Leiva et autres

us, mx, pe, hu, cn, jp, il, br, in, se, gb (code pays fourni par la source)

Clinical and molecular characteristics of early progressors (EPs) and long-term progression-free survivors (LTPs) from the phase 3 ADRIATIC trial of consolidation durvalumab (D) vs placebo (P) after concurrent chemoradiotherapy (cCRT) in limited-stage small-cell lung cancer (LS-SCLC).

David A. Barbie, Mingchao Xie, Maria A.S. Broggi, Ying Cheng et autres

us, jp, cn, kr, es, de, tr, ca, nl (code pays fourni par la source)

Figure 5 from Preclinical Evaluation of AZD6422, an Armored Chimeric Antigen Receptor T Cell Targeting CLDN18.2 in Gastric, Pancreatic, and Esophageal Cancers

Allison M. Barrett, Zachary T. Britton, Rosa A. Carrasco, Shannon Breen et autres

Figure 2 from Preclinical Evaluation of AZD6422, an Armored Chimeric Antigen Receptor T Cell Targeting CLDN18.2 in Gastric, Pancreatic, and Esophageal Cancers

Allison M. Barrett, Zachary T. Britton, Rosa A. Carrasco, Shannon Breen et autres

Figure 3 from Preclinical Evaluation of AZD6422, an Armored Chimeric Antigen Receptor T Cell Targeting CLDN18.2 in Gastric, Pancreatic, and Esophageal Cancers

Allison M. Barrett, Zachary T. Britton, Rosa A. Carrasco, Shannon Breen et autres

Figure 1 from Preclinical Evaluation of AZD6422, an Armored Chimeric Antigen Receptor T Cell Targeting CLDN18.2 in Gastric, Pancreatic, and Esophageal Cancers

Allison M. Barrett, Zachary T. Britton, Rosa A. Carrasco, Shannon Breen et autres

Figure 4 from Preclinical Evaluation of AZD6422, an Armored Chimeric Antigen Receptor T Cell Targeting CLDN18.2 in Gastric, Pancreatic, and Esophageal Cancers

Allison M. Barrett, Zachary T. Britton, Rosa A. Carrasco, Shannon Breen et autres

Data from Preclinical Evaluation of AZD6422, an Armored Chimeric Antigen Receptor T Cell Targeting CLDN18.2 in Gastric, Pancreatic, and Esophageal Cancers

Allison M. Barrett, Zachary T. Britton, Rosa A. Carrasco, Shannon Breen et autres

Supplementary Data1 from Preclinical Evaluation of AZD6422, an Armored Chimeric Antigen Receptor T Cell Targeting CLDN18.2 in Gastric, Pancreatic, and Esophageal Cancers

Allison M. Barrett, Zachary T. Britton, Rosa A. Carrasco, Shannon Breen et autres